IL319478A - Anti-ccr8 antibodies - Google Patents

Anti-ccr8 antibodies

Info

Publication number
IL319478A
IL319478A IL319478A IL31947825A IL319478A IL 319478 A IL319478 A IL 319478A IL 319478 A IL319478 A IL 319478A IL 31947825 A IL31947825 A IL 31947825A IL 319478 A IL319478 A IL 319478A
Authority
IL
Israel
Prior art keywords
ccr8
antibody
antibodies
seq
cells
Prior art date
Application number
IL319478A
Other languages
English (en)
Hebrew (he)
Inventor
Andrew J Mccluskey
Paustian Amanda M Schmidt
Jane Seagal
Julie L Wilsbacher
Original Assignee
Abbvie Inc
Andrew J Mccluskey
Paustian Amanda M Schmidt
Jane Seagal
Julie L Wilsbacher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc, Andrew J Mccluskey, Paustian Amanda M Schmidt, Jane Seagal, Julie L Wilsbacher filed Critical Abbvie Inc
Publication of IL319478A publication Critical patent/IL319478A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL319478A 2021-07-27 2022-07-27 Anti-ccr8 antibodies IL319478A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163226118P 2021-07-27 2021-07-27
PCT/US2022/074214 WO2023010054A1 (en) 2021-07-27 2022-07-27 Anti-ccr8 antibodies

Publications (1)

Publication Number Publication Date
IL319478A true IL319478A (en) 2025-05-01

Family

ID=82898810

Family Applications (2)

Application Number Title Priority Date Filing Date
IL319478A IL319478A (en) 2021-07-27 2022-07-27 Anti-ccr8 antibodies
IL307533A IL307533B2 (en) 2021-07-27 2022-07-27 Anti-ccr8 antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL307533A IL307533B2 (en) 2021-07-27 2022-07-27 Anti-ccr8 antibodies

Country Status (27)

Country Link
US (1) US11639393B2 (cg-RX-API-DMAC7.html)
EP (2) EP4491635A3 (cg-RX-API-DMAC7.html)
JP (2) JP7638935B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250135339A (cg-RX-API-DMAC7.html)
CN (1) CN117425677A (cg-RX-API-DMAC7.html)
AR (1) AR126578A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022317803A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024837A2 (cg-RX-API-DMAC7.html)
CA (1) CA3220121A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023015915A2 (cg-RX-API-DMAC7.html)
DK (1) DK4214240T3 (cg-RX-API-DMAC7.html)
ES (1) ES2995868T3 (cg-RX-API-DMAC7.html)
FI (1) FI4214240T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241561T1 (cg-RX-API-DMAC7.html)
HU (1) HUE069018T2 (cg-RX-API-DMAC7.html)
IL (2) IL319478A (cg-RX-API-DMAC7.html)
LT (1) LT4214240T (cg-RX-API-DMAC7.html)
MX (1) MX2023014154A (cg-RX-API-DMAC7.html)
PL (1) PL4214240T3 (cg-RX-API-DMAC7.html)
PT (1) PT4214240T (cg-RX-API-DMAC7.html)
RS (1) RS66234B1 (cg-RX-API-DMAC7.html)
SA (1) SA523451582B1 (cg-RX-API-DMAC7.html)
SI (1) SI4214240T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400483T1 (cg-RX-API-DMAC7.html)
TW (2) TWI920354B (cg-RX-API-DMAC7.html)
WO (1) WO2023010054A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202309516B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI890283B (zh) 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
CN120076829A (zh) 2022-10-18 2025-05-30 明治制果药业株式会社 T细胞肿瘤的治疗剂
TW202436351A (zh) 2023-02-06 2024-09-16 德商拜耳廠股份有限公司 Ccr8抗體及dgk抑制劑之組合
WO2024248037A1 (ja) 2023-05-30 2024-12-05 塩野義製薬株式会社 Ccr8を抗原として認識する二重特異性抗体
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗fap-light融合蛋白及其用途
CN122459678A (zh) 2023-12-29 2026-07-24 百时美施贵宝公司 KRAS抑制剂与Treg耗竭剂的组合疗法
WO2025186043A1 (en) 2024-03-06 2025-09-12 Bayer Aktiengesellschaft Pharmaceutical formulation for anti-ccr8 antibodies
WO2025259871A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
US10087259B1 (en) 2014-04-28 2018-10-02 Memorial Sloan Kettering Cancer Center Depleting tumor-specific tregs
CN109715653A (zh) 2016-05-16 2019-05-03 驰科迈博有限责任公司 肿瘤浸润调节性t细胞中被选择性地去调节的标志物
WO2018112032A1 (en) 2016-12-13 2018-06-21 President And Fellows Of Harvard College Methods and compositions for targeting tumor-infiltrating tregs using inhibitors of ccr8 and tnfrsf8
PT3431105T (pt) 2017-03-29 2020-03-11 Shionogi & Co Composição medicinal para tratamento de cancro
BR112021011431A2 (pt) * 2018-12-27 2021-11-23 Univ Osaka Anticorpo monoclonal ou um fragmento de anticorpo do mesmo que se liga ao ccr8, seu uso, bem como composição farmacêutica, polinucleotídeo, vetor de expressão e kit
AU2021205877B2 (en) 2020-01-06 2024-06-20 Vaccinex, Inc. Anti-CCR8 antibodies and uses thereof
TWI890283B (zh) * 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
US20250019449A1 (en) 2020-03-05 2025-01-16 Memorial Sloan Kettering Cancer Center Anti-ccr8 agents
AU2021244200A1 (en) 2020-03-23 2022-11-24 Bristol-Myers Squibb Company Anti-CCR8 antibodies for treating cancer
TW202216771A (zh) 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
JP7610302B2 (ja) 2020-08-28 2025-01-08 ハーバー・バイオメド・(シャンハイ)・カンパニー・リミテッド Ccr8抗体及びその用途
EP4228764A1 (en) 2020-10-14 2023-08-23 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
AU2021277712B2 (en) 2020-10-16 2023-05-25 LaNova Medicines Limited Anti-CCR8 monoclonal antibodies and uses thereof
WO2022136649A1 (en) 2020-12-24 2022-06-30 Oncurious Nv Non-blocking human ccr8 binders
EP4267617A1 (en) 2020-12-24 2023-11-01 Vib Vzw Human ccr8 binders

Also Published As

Publication number Publication date
CA3220121A1 (en) 2023-02-02
TWI920354B (zh) 2026-04-01
CN117425677A (zh) 2024-01-19
LT4214240T (lt) 2024-11-25
US11639393B2 (en) 2023-05-02
EP4491635A2 (en) 2025-01-15
SA523451582B1 (ar) 2025-04-26
ZA202309516B (en) 2025-03-26
HUE069018T2 (hu) 2025-02-28
IL307533A (en) 2023-12-01
KR20240067052A (ko) 2024-05-16
AR126578A1 (es) 2023-10-25
HRP20241561T1 (hr) 2025-02-14
JP2025081477A (ja) 2025-05-27
SI4214240T1 (sl) 2025-02-28
US20230048553A1 (en) 2023-02-16
DK4214240T3 (da) 2024-11-18
AU2022317803A1 (en) 2023-10-26
EP4491635A3 (en) 2025-04-02
JP7638935B2 (ja) 2025-03-04
JP2023018678A (ja) 2023-02-08
ES2995868T3 (en) 2025-02-11
PL4214240T3 (pl) 2025-01-07
BR112023024837A2 (pt) 2024-02-20
FI4214240T3 (fi) 2024-11-14
EP4214240B1 (en) 2024-10-09
TW202611084A (zh) 2026-03-16
TW202321304A (zh) 2023-06-01
PT4214240T (pt) 2024-11-25
EP4214240A1 (en) 2023-07-26
CO2023015915A2 (es) 2023-12-11
IL307533B2 (en) 2025-08-01
WO2023010054A1 (en) 2023-02-02
SMT202400483T1 (it) 2025-01-14
MX2023014154A (es) 2024-05-14
RS66234B1 (sr) 2024-12-31
KR102860769B1 (ko) 2025-09-18
IL307533B1 (en) 2025-04-01
KR20250135339A (ko) 2025-09-12

Similar Documents

Publication Publication Date Title
JP7855519B2 (ja) がんを処置するための抗ccr8抗体
IL307533B2 (en) Anti-ccr8 antibodies
US11660340B2 (en) Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
US11505605B2 (en) T cell-redirected antigen-binding molecule for cells having immunosuppression function
US11649293B2 (en) Method for enhancing humoral immune response
KR20210143192A (ko) 변형된 Fc 단편, 이를 포함하는 항체 및 이의 응용
CN106459206A (zh) 免疫活化抗原结合分子
EP4493592A1 (en) Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
US12435159B2 (en) Anti-human GRP94 antibodies and uses
CN117203341A (zh) 用于治疗或预防炎症性疾病的抗人pd-1激动剂抗体和含有其的药物组合物
HK40100657A (en) Anti-ccr8 antibodies
HK40100657B (en) Anti-ccr8 antibodies
BR122025022218A2 (pt) Anticorpo anti-ccr8 e composição farmacêutica
BR122024013309B1 (pt) Anticorpos anti-ccr8 e composição compreendendo os mesmos
BR122024013309A2 (pt) Anticorpos anti-ccr8 e composição compreendendo os mesmos
KR20260047587A (ko) 항-ox40l 항체 및 이의 용도
US12545732B2 (en) PD-1 antigen-binding protein and use thereof